ReviewHuman gene therapy2013
An emerging adeno-associated viral vector pipeline for cardiac gene therapy.
Review in Human gene therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- MicroRNAs in Atrial Fibrillation: from Expression Signatures to Functional Implications.Cardiovascular drugs and therapy · 2017Pooled it
- Current Landscape of Gene Therapy for the Treatment of Cardiovascular Disorders.Current gene therapy · 2024Review
- AAV capsid engineering identified two novel variants with improved in vivo tropism for cardiomyocytes.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Article
- Potential Applications for Targeted Gene Therapy to Protect Against Anthracycline Cardiotoxicity:JACC. CardioOncology · 2021Review
- Targeted nanoscale therapeutics for myocardial infarction.Biomaterials science · 2021Review
- Bioengineering Technologies for Cardiac Regenerative Medicine.Frontiers in bioengineering and biotechnology · 2021Review
- Gene therapy for inherited arrhythmias.Cardiovascular research · 2020Review
- Reviewing the Limitations of Adult Mammalian Cardiac Regeneration: Noncoding RNAs as Regulators of Cardiomyogenesis.Biomolecules · 2020Review
- High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease.Drugs in context · 2018Review
- Primary genetic disorders affecting high density lipoprotein (HDL).Drugs in context · 2018Review
- Use of Adeno-Associated Virus Vector for Cardiac Gene Delivery in Large-Animal Surgical Models of Heart Failure.Human gene therapy. Clinical development · 2017Review
- Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease.Human gene therapy · 2016Article
- Intracoronary Cytoprotective Gene Therapy: A Study of VEGF-B167 in a Pre-Clinical Animal Model of Dilated Cardiomyopathy.Journal of the American College of Cardiology · 2015Article
- Beyond traditional pharmacology: new tools and approaches.British journal of pharmacology · 2015Review
- Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success--a personal perspective.Human gene therapy · 2015Review
- HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis.Frontiers in pharmacology · 2015Review
- Copackaging of multiple adeno-associated viral vectors in a single production step.Human gene therapy methods · 2014Article
- Gene therapy: charting a future course--summary of a National Institutes of Health Workshop, April 12, 2013.Human gene therapy · 2014Review
- Recombinant adeno-associated virus vectors in the treatment of rare diseases.Expert opinion on orphan drugsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The naturally occurring adeno-associated virus (AAV) isolates display diverse tissue tropisms in different hosts. Robust cardiac transduction in particular has been reported for certain AAV strains. Successful applications of these AAV strains in preclinical and clinical settings with a focus on treating cardiovascular disease continue to be reported. At the same time, these studies have highlighted challenges such as cross-species variability in AAV tropism, transduction efficiency, and immunity. Continued progress in our understanding of AAV capsid structure and biology has provided the rationale for designing improved vectors that can possibly address these concerns. The current report provides an overview of cardiotropic AAV, existing gaps in our knowledge, and newly engineered AAV strains that are viable candidates for the cardiac gene therapy clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.